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Drugs against multiple targets may overcome the many limitations of single targets and achieve a
more effective and safer control of the disease. Numerous high-throughput experiments have been
performed in this emerging ﬁeld. However, systematic identiﬁcation of multiple drug targets and
their best intervention requires knowledge of the underlying disease network and calls for
innovative computational methods that exploit the network structure and dynamics. Here, we
develop a robust computational algorithm for ﬁnding multiple target optimal intervention (MTOI)
solutions in a disease network. MTOI identiﬁes potential drug targets and suggests optimal
combinations ofthetargetintervention thatbestrestore thenetworkto anormal state, whichcan be
customer designed. We applied MTOI to an inﬂammation-related network. The well-known side
effectsofthetraditionalnon-steriodal anti-inﬂammatorydrugs andtherecentlyrecalledVioxxwere
correctlyaccountedforinour networkmodel.AnumberofpromisingMTOIsolutions werefoundto
be both effective and safer.
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Introduction
The one-target one-drug paradigm has been the dominating
drug discovery approach in the past decades (Lindsay, 2003).
The paradigm focuses on identifying a single chemical entity
that binds to a single target. This single-target-based method
was believed to be more efﬁcient than the traditional in vivo
approach because of its greater screening capacity and the
associated rational drug discovery programs. However, the
number of successful drugs did not increase as expected (FDA,
2004;Sams-Dodd,2005).Problemsoccurwhenthetargetitself
is uncertain and when multiple targets have to be involved in
disease control. It was long realized that the behavior of drug
molecules in a disease network can be complex. Drugs with
efﬁcacy predicted only from their speciﬁc target-binding
experiment may not have the same effect in clinical treatment
due to interactions between pathways in the disease network
(Csermely et al, 2005). Side effects often occur because of the
unexpected effects of the drug. For example, in the case of
inﬂammation, two pathways, the COX (cyclooxygenase)
pathway and the 5-LOX (5-lipoxygenase) pathway, produce
inﬂammatory mediators. Molecules important for normal
physiology, such as vasoactive substance prostacyclin (PGI2)
and thromboxane A2 (TXA2), are metabolized in the same
system as well. Selective COX-2 inhibitors can effectively
prohibit the production of certain inﬂammatory mediators,
such as prostaglandins (PGs). But this leads to a concomitant
increase of leukotrienes (LTs), another kind of inﬂammatory
mediator (Rainsford, 1993; Brooks, 1998). Even worse, it
causes a cardiovascular side effect due to the induced
unbalance between PGI2 and TXA2 (Wang et al, 2005).
Toovercomethelimitationsofthesingle-target-baseddrugs,
growing attention has been paid to drug discoveries involving
multiple targets and at the level of disease networks (Csermely
et al, 2005; Frantz, 2005; Kitano, 2007; Zimmermann et al,
2007). Some clinical data support the beneﬁts of multi-target
drugs. Examples of such strategy can be found in the
combinatorial therapy of AIDS, atherosclerosis, cancer, and
depression (Korcsmaros et al, 2007). The discovery that some
traditional remedies and empirically selected drugs act on
& 2008 EMBO and Macmillan Publishers Limited Molecular Systems Biology 2008 1
Molecular Systems Biology 4; Article number 228; doi:10.1038/msb.2008.60
Citation: Molecular Systems Biology 4:228
& 2008 EMBO and Macmillan Publishers Limited All rights reserved 1744-4292/08
www.molecularsystemsbiology.commultiple targets also suggests that multi-target drugs can be
beneﬁcial(Sharometal,2004).Severalmarketingsuccessesof
multicomponent therapies have already been reported: sal-
meterol/ﬂuticasone (Advair; GlaxoSmithKline) (Nelson,
2001), nicotinic acid/lovastatin (Advicor; Kos Pharmaceuti-
cals) (Gupta and Ito, 2002; Bays et al, 2003) and AZT–3TC
(Combivir; GlaxoSmithKline) (Larder et al, 1995).
Adiverserangeofworkhasbeencarriedoutintheemerging
ﬁeld of multi-target drug design. Cell-based phenotypic assays
were employed to construct better models of disease systems
(Borisy et al, 2003; Zimmermann et al, 2007). Ligand
promiscuity was studied to design inhibitors against multiple
targets (Hopkins et al, 2006). Disease-related networks were
reconstructed to gain insights at a global and systems level
(Bouwmeester et al, 2004; Duarte et al, 2007). Various
databases have been developed for systematic analysis (Peri
et al, 2003; Ganter et al, 2005). Theoretical and computational
studiesinthisandrelatedareasarealsopickinguppace.Itwas
proposed that system-oriented drug design should take into
account the intrinsic properties of biological systems, for
example, robustness (Kitano, 2007). Many mathematical
models of disease-relevant pathways have been constructed
with the potential to elucidate underlying mechanisms of
diseases and to identify treatment strategies (Schoeberl et al,
2002; Rajasethupathy et al, 2005). Network properties were
analyzed to ﬁnd potential drug targets and to understand
connectivity between them (Sung and Simon, 2004; Hwang
et al, 2008). However, practical and systematic computational
strategies and methods are in need for multi-target drug design
based on disease network modeling.
Inthepresentstudy,wedevelopacomputationalmethodfor
ﬁnding multiple target optimal intervention (MTOI) solutions
in a disease network. For a given disease network, the method
tries to identify effective points of intervention and the
combination of interventions that can best restore the disease
network to a desired normal state. Instead of focusing on a
single drug target, the MTOI method analyzes the relevant
network as a system to extract information about the inter-
conversion of the disease and the normal state of the network.
The method has two end products: (1) it generates a list of
potential drug targets in a given disease network and their
corresponding regulation (inhibition or activation) needed for
treatment; (2) it suggests a list of optimal combinatorial multi-
target intervention solutions for any user-deﬁned therapeutic
requirements.Asaconcreteexample,wehaveappliedMTOIto
an inﬂammation-related network—the arachidonic acid (AA)
metabolic network (AAnetwork). The long history of the anti-
inﬂammatory struggle has not yet succeeded in safe and
effective drugs, but has accumulated abundant experimental
and clinical data. This allowed us to construct an AAnetwork
model in human polymorphonuclear leukocyte (PMN), pre-
sented in our earlier study (Yang et al, 2007). Here, we further
extended this model to other cell types to construct a more
accurate model with improved toxicity prediction. With this
newAAnetwork,wesimulatedthedrugeffectsofpopularanti-
inﬂammatorymedicines,suchasaspirin,Vioxxandsoon.The
known bleeding or cardiovascular side effects of these drugs
were correctly reproduced. We applied MTOI to the new
AAnetwork and identiﬁed ﬁve drug targets in the network:
phospholipase A2 (PLA2), PGE synthetase (PGES), COX-2,
5-LOX and LTA4 hydrolase (LTA4H). A number of optimal
combinations of target intervention (MTOI solutions) were
found that are both effective in controlling the inﬂammation
mediators and are safe with minimal side effects.
Results
MTOI for disease network
Feedback loops, cross-talk and other network-intrinsic proper-
ties can make the effects of drug molecules much more
complicated than what a linear one-drug one-target approach
would predict (Araujo et al, 2007; Kitano, 2007; Lehar et al,
2007). It is therefore necessary to systematically analyze the
disease network as a whole to ﬁnd points of intervention that
are the most effective and with the least side effects. We have
developed a computational method for ﬁnding multiple target
intervention solutions with user-deﬁned therapeutic effects.
This method contains two stages. The ﬁrst stage is the
identiﬁcation of the potential drug targets. This stage can be
skipped if the drug targets have been identiﬁed or are given.
The second stage is the search and optimization of multiple
target intervention solutions, which are the core functions of
the method. Two network states are deﬁned: the disease state
and the normal (or desired) state. The disease state is a
network state in which the production of disease-related
molecules is abnormal. The normal (or desired) state is the
network state one would like to achieve after taking medicine,
which can be customer-deﬁned. The main procedure of MTOI
is to perturb the network and optimize it toward the desired
state. The procedure can be carried out by various optimiza-
tion algorithms; here, we used Monte Carlo simulated
annealing (MCSA). By comparing the perturbed network that
has achieved the desired state with the network that generated
the disease state, we are able to ﬁnd potential drug targets and
the MTOI solutions that best restore the disease network state
to the desired one.
Drug target identiﬁcation
Before searching for the MTOI solutions, we need to identify
the potential drug targetsin the disease network. These targets
are selected according to a criterion that measures their robust
‘inﬂuence’ in restoring the network state when being
perturbed. Speciﬁcally, we deﬁne an objective function to be
the difference between the current network state and the user-
deﬁned desired state. The function is then minimized with an
MCSA algorithm (Figure 1), by changing the activity of drug
targetcandidates,untilthenetworkstateissufﬁcientlycloseto
the desired one. We record the activities of drug target
candidates in the ﬁnal state, and this is called an acceptable
MCSA run. After many acceptable runs of MCSA, many sets of
activities of drug target candidates that achieved the desired
state are obtained. Two parameters are then calculated to
analyze the robust inﬂuence of a drug target candidate on the
network state (see details in Materials and methods). One is
the standard deviation (s.d.) of the activities of the drug target
candidate in all acceptable runs. This parameter describes the
consistency of the activity of the candidate in restoring the
desired state. The other is the median deviation (m.d.) of the
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that of the disease state. Median deviation describes how far
on average, does the activity of drug target candidate in the
desired state deviate from that in the disease state. Drug
target candidates with larger m.d. are more responsive to
perturbations that restore the network to the desired state. The
absolute value of the ratio of m.d. to s.d. is used to rank drug
target candidates. The larger the |m.d./s.d.| is, the more likely
that perturbing the target will have a signiﬁcant effect in
steering the network toward the desired state. Median
deviation also provides information about the manner of
regulation that should be adopted in the treatment. When
the m.d. value is negative, the corresponding drug target
should be inhibited in the treatment; otherwise, the target
should be activated. With all the information above, a set of
drug targets is selected, which will be the subject of the
multiple targets control solution search in stage 2 of MTOI
described below.
Optimal multiple targets intervention solutions
With the potential drug targets in the disease network
identiﬁed, we search for the best sets of combinatorial control
on these targets that can restore the network to the desired
state. Similar to stage 1, MCSA is utilized to search for
solutions that can turn the network state into the desired one
(Figure 1). The difference with stage 1 is that (1) the
optimization is performed only on a pre-speciﬁed set of drug
targets that are selected in stage 1 and (2) the perturbation on
the targets is modeled in detail with corresponding equations
of inhibition or activation (see details in Materials and
methods). Therefore, at the end of an acceptable MCSA run,
which resulted in a network state sufﬁciently close to the
desired one, we obtain a set of inhibition and/or activation
intensities on the drug targets. We call this set an optimal
solution of the multi-target control for the speciﬁed targets.
After many runs of MCSA, we can, in principle, ﬁnd all
possible optimal solutions for the combinatorial multi-
Figure 1 The ﬂow chart of MTOI. MTOI functions in two stages: drug target search and optimal multi-target control solution identiﬁcation. MCSA is employed as the
optimization method. Differences in stages 1 and 2 are highlighted by light and dark gray, respectively.
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Application of MTOI to inﬂammation network
The AAnetwork model in human PMN, endothelial and
platelet cells
Inﬂammation is a basic way in which the body reacts to
infection, irritation or other injuries. Standard drug targets
suchasCOX-2and5-LOXareamongthekeyenzymesinvolved
in the network responsible for generating inﬂammation
mediators. However, essentially all single-target drugs so far
have side effects in anti-inﬂammatory treatment. To ﬁnd safer
multi-target intervention solutions, we employed MTOI in an
inﬂammation-related network, the AA metabolic network
(AAnetwork) with a multi-cellular ensemble of human PMN,
endothelial (EC)andplatelet(PLT)cells(Figure2, theseparate
AAnetworks in PMN, EC and PLTcan be found in Supplemen-
tary Figure S1). The model was developed partly based on our
previousAAnetworkmodelforhumanPMN(Yangetal,2007).
However, the metabolism of AA in different cell types is
different. LTs are the major inﬂammatory mediators produced
in PMN (Simmons et al, 1983; Abbate et al, 1990). PGI2,
PGF2a and PGE2 are the main eicosanoids detected in EC
(Camacho et al, 1998). PGE2 is an important inﬂammatory
mediator causing fever and pain (Ivanov and Romanovsky,
2004; Samuelsson et al, 2007), whereas PGI2 inhibits PLT
aggregationandrelaxessmoothmuscle(Honnetal,1981).PLT
cellsproduceabundantTXA2,whichisapotentinducerofPLT
aggregation and vasoconstriction (Smith et al, 1980). The new
AAnetwork model produced a better simulation of inﬂamma-
tion course in human blood vessel. In addition, the ratio of
PGI2/TXA2 can be calculated to evaluate cardiovascular or
bleeding side effects of the drugs (Kiviniemi et al, 1987; Kyrle
et al, 1989; Martin et al, 1996; Kobayashi et al, 2004).
Ordinary differential equations (ODEs) were constructed to
simulate the dynamic course of AA metabolism, where 24, 29
and 11 equations were used for PMN, EC and PLT, respectively
(see details in Supplementary information). The concentra-
tionsofPMN,ECandPLTinthemodelwereadoptedaccording
to their ratios in the human vessel (see details in Materials and
methods). As signaling interactions among cells are complex
in real circumstances and there is not enough experimental
data,wedidnotinclude theminthecurrentmodel.Amongthe
117 parameters in the ODE model, 46 were taken directly from
experiments, whereas the others were determined by para-
meter ﬁtting to experimental curves (see details in Supple-
mentary information), including the production of LTB4 and
o-LTB4 in PMN (Shak and Goldstein, 1984), the production of
PGF2a, PGE2 and 6-keto-PGF1a in EC (Camacho et al, 1998),
and the production of TXA2 and TXB2 in PLT (Anderson et al,
1978). It is to be noted that in addition to these parameters, the
concentrationsoftheenzymesandtheinitialconcentrationsof
metabolites are also variables. Multiple parameter sets were
obtained, which ﬁt the curves equally well (Supplementary
Table SI).
Drug targets search in the AAnetwork
Weperformed MTOIto identifydrug targetsin theAAnetwork.
The disease state of the AAnetwork is deﬁned as a state where
the output of PGs and LTs is markedly above the normal level.
As the experimental curves used in parameter ﬁtting corre-
sponded to the abnormal metabolism of PGs and LTs, we used
the parameter sets derived there to describe the disease state
(see details in ‘The AAnetwork model in human PMN,
Figure 2 The metabolic network of arachidonic acid inhuman PMN, EC and PLT. Two pathways are responsible for the production of inﬂammatory mediators: COX-2
pathway and 5-LOX pathway. LTB4 and PGE2 are major inﬂammatory mediators produced in the AAnetwork. PGI2 and TXA2 are vasoactive molecules, the abnormal
production of which causes bleeding and cardiovascular disease. The separate AAnetworks in PMN, EC and PLT can be found in Supplementary Figure S1.
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as low output of inﬂammatory mediators, that is, the
cumulative output of LTB4 and PGE2 should be smaller than
10% of that in the disease state, respectively. The threshold of
10% was selected here arbitrarily as it is impossible to give a
deﬁnite cutoff to divide normal from disease in this case. The
situation would depend on conditions such as the type of
inﬂammation, the development level of disease and so on. We
have tested the effect of cutoff on the results by changing the
threshold to 20%. The same drug targets were selected by the
new threshold (Supplementary Table SII). The entire 17
enzymes in the AAnetwork were selected as drug target
candidates and their activities (Kcat [E]/Km, where [E] is the
concentration of an enzyme) were perturbed during optimiza-
tion. The absolute value of m.d./s.d. was calculated to
determine the importance of the enzyme, and the correspond-
ing manner of regulation was determined by the sign of m.d.
(see details in Materials and methods). To get reliable results,
many runs of MCSAwere performed until the s.d. and m.d. for
all candidates converged. As multiple parameter sets can ﬁt
the experimental data equally well, the drug targets identiﬁed
can, in principle, depend on which parameter set we use.
However, we note that the top drug targets (scored according
to |m.d./s.d.|) are always the same, independent of the
parameter set used, although their rank order may vary. This
implies that the results of MTOI are rather robust, which
depend moreon the network structure than on thevalue of the
individual parameters. Table I shows the result of the search
for drug targets of one particular parameter set derived from
the parameter ﬁtting. Results for other parameter sets are
summarized in Supplementary Table SII. In the ﬁve parameter
setsthat westudied,theenzymesidentiﬁedastoptheﬁveinat
least four parameter sets were selected as drug target
candidates. They are PLA2, LTA4H, COX-2, 5-LOX and PGES.
Interestingly, all the ﬁve drug targets have negative m.d.
values, indicating that the corresponding drugs should be
inhibitors. Some other enzymes also have close |m.d./s.d.|
values to the top ﬁve targets, such as PHGPx in Table I.
However, they were not selected as drug targets for our further
studies in stage 2, because their m.d. values are positive. Their
corresponding drugs would be enzyme activators, which is
normally difﬁcult to realize in drug development.
MTOI solutions for the AAnetwork
We performed MTOI to search for optimal multi-target anti-
inﬂammatory intervention solutions. The disease state at this
stage is the same as in the previous section, modeled by the
parameter sets derived from ﬁtting experimental curves. The
desired state, on the other hand, is slightly modiﬁed. In
addition to reducing the inﬂammatory mediators, we have
added requirements that minimize possible side effects.
Speciﬁcally, we require that the desired state should satisfy
the following conditions: (1) the cumulative production of
LTB4 must be below 10% of that in the disease state; (2) the
cumulative production of PGE2 must be below 10% of that in
the disease state and (3) the change in the PGI2/TXA2 ratio
between the desired and disease states must be smaller than a
preset small value (here, we use 20%). This condition ensures
that the drugs will not break the balance between PGI2 and
TXA2 to cause cardiovascularor bleeding side effects.We took
the top ﬁve drug targets identiﬁed in stage 1 (in the previous
section) for further optimization of multi-target control in this
stage. Other enzymes have not been selected for their low
|m.d./s.d.| value and positive m.d. Considering that most
COX-2 inhibitors will inhibit COX-1 at the same time to a
certain extent due to the high homology of the two enzymes,
we included COX-1 in the drug target list and but constrained
because the inhibition on COX-2 and COX-1 should coexist.
Thus, six drug targets were selected at stage 2, in which ﬁve of
them (excluding COX-1) were predicted to be subjected to
inhibition at stage 1. We assumed that the drugs against these
enzymes were all competitive inhibitors and deﬁned their
inhibition intensity as the ratio of inhibitor concentration to
inhibition constant ([I]/Ki). The values of [I]/Ki for the ﬁve
drugs were perturbed in MCSA and the difference between the
present network and the desired states was employed as the
objective function for minimization (see details in Materials
and methods).
To obtain reliable results, many runs of MCSA were
performed. The set of [I]/Ki for inhibiting the six enzymes at
theendofeachacceptablerunwouldcorrespondtoanoptimal
multi-target intervention solution. These solutions frommulti-
ple runs were then clustered into distinct groups. We note that
whereasatstage1 allparametersetsstudied gavethesametop
ﬁve drug targets, the results of stage 2 depended somewhat on
parameter sets. We have used ﬁve different parameter sets in
the study of stage 2. Although there is a large overlap in the
solutions from different parameter sets, some solutions were
found only in individual parametersets (Table II). Perhaps this
is not very surprising given the great uncertainty about the
parameters. What is interesting is that there are common
features in solutions among all the parameter sets. Thus, we
can still make some concrete conclusions about the MTOI
solutions even with partly uncertain parameters.First, none of
the solutions in any parameter sets is single target, implying
the necessity for multi-target control in this network. Second,
the solutions involving the larger number of targets are more
robust. The six-targetsolution and certain ﬁve-and four-target
Table I Results from drug targets search by MTOI
Rank Enzyme abs(m.d./s.d.) m.d.
1 PLA2 0.9081  1
2 LTA4H 0.8135  0.84
3 5-LOX 0.774  0.88
4 PGES 0.7199  0.72
5 COX-2 0.6748  0.72
6 PHGPx 0.538 0.6
7 TXAS 0.1756 0.2
8 CYP4F3 0.1063 0.12
9 PGDS 0.1041 0.12
10 12-LOX 0.1022 0.12
11 15-LOX 0.0699 0.08
12 CR 0.0349 0.04
13 15-PGDH 0 0
14 COX-1 0 0
15 9-KPR 0 0
16 PGFS 0 0
17 PGIS 0 0
The parameter set used is the same as in Figure 3. The top ﬁve enzymes were
selected asdrug targetsand theircorresponding regulations were all predicted to
be inhibition.
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result suggests a strategy when facing uncertainties in
parameters: simultaneous intervention of many targets that
are ‘inﬂuential’ for the network state. If one views genetic and
other variations in the system as a source of parameter
uncertainty, this strategy may also be used to maximize the
‘bet’inthecaseoflimitedinformation.Ideally,theefﬁcacyand
safety of a robust multi-target intervention solution should not
be sensitiveto smallchanges in the inhibition intensities of the
solution. We deﬁned this sensitivity as the ratio of the
percentage change of the objective function over that of the
inhibition intensities (see details in Materials and methods).
As can be seen from Table II, this sensitivity is extremely small
for the MTOI solutions we found.
Furthermore, we analyzedtheeffectiveand saferangeof the
drug intensity ([I]/Ki) of the multi-target solutions (‘therapeu-
tic window’). These distributions of [I]/Ki are obtained by
sampling the intensity [I]/Ki of the inhibitors to the multi-
targets speciﬁed by the solution, and recording the combina-
tion of [I]/Ki that can change the disease state into the desired
state. As the intensity space [I]/Ki is highly dimensional (with
thedimensionalitybeingthenumberoftargets),weprojectthe
distribution onto every pair of two dimensions. In Figure 3, we
show the [I]/Ki distribution of the inhibitors for two different
MTOI solutions, with three targets(Figure3A) and four targets
(Figure 3B), respectively. Results of other MTOI solutions are
listed in the Supplementary information. In general, inhibitors
against more drug targets have larger therapeutic windows. It
is to be noted that when all six targets are inhibited, the [I]/Ki
distributions not only have very wide ranges but are also
essentiallyuncorrelatedwitheachother.Thismakesthemulti-
targetsolutions much more practical,both in terms of the drug
design and of the clinical use. The inhibition of PLA2 and/or
COX-1/2 has strong effect on the ratio of PGI2/TXA2. When
PLA2 is not inhibited, the ratio of COX-1 and COX-2 inhibition
has to be ﬁxed within a narrow range to maintain the ratio of
PGI2/TXA2 (Figure 3A). Balanced inhibition of these two COX
isoenzymes wouldbe important to avoidside effects.Selective
COX-1/2 inhibitors were known to conduct either gastro-
intestinal or cardiovascular damage (Suleyman et al, 2007).
With balanced inhibition, the therapeutic window of COX
inhibition can be very large. As COX-1 and COX-2 are
isoenzymes, designing an inhibitor with a ﬁxed ratio of
afﬁnities should not be difﬁcult. This ﬁxed ratio of COX-1/2
inhibition is no longer necessary when PLA2 is inhibited
simultaneously (Figure 3B).
Veriﬁcation of the AAnetwork model by simulating the
effects of known non-steriodal anti-inﬂammatory drugs
IftheconstructedAAnetworkisreasonablyreliable,weshould
be able to simulate the behavior of anti-inﬂammatory drugs to
assess their efﬁcacy and potential side effects within the
network model. We have made so far a long list of anti-
inﬂammatory drugs covering most currently used non-
steriodal anti-inﬂammatory drugs (NSAIDs). They include
non-selective NSAIDs, selective COX-2 inhibitors, and dual
functional COX-2/5–LOX inhibitor. The relative IC50 values of
these medicines were taken from the published experimental
data (Patrono et al, 2001; Vidal et al, 2007). The ratio of PGI2/
TXA2 was calculated as the indicator for side effects—a large
increase in this ratio after taking the medicine would imply
bleeding risks, whereas a signiﬁcant decrease of the ratio
wouldraisecardiovascularrisks(Martinetal,1996;Kobayashi
et al, 2004). The simulation results are shown in Table III.
Aspirin is a strong COX-1 inhibitor and a mild COX-2
inhibitor. COX-1 is the main COX isozyme in PLT, which is
responsible for the major production of TXA2 in the model. A
low concentration of aspirin is reported to have an antithrom-
botic effect (Patrono et al, 2001). In our simulation, as aspirin
strongly inhibited the production of TXA2, the value of PGI2/
TXA2 was much larger than before the administration of
medicine. Thus, aspirin can prevent myocardial infarction and
ischemic stroke but raise the risk of bleeding. When the
relative IC50(COX-1:COX-2) increases, the inhibition effect of
the medicine on TXA2 production and PLT aggregation
decreases when compared with their inhibition effect on
PGI2 production (Sun and Li, 2000; Van Hecken et al, 2000).
The bleeding risk of NSAIDs lessens following the reduced
inhibitionofCOX-1.Inoursimulation,thevalueofPGI2/TXA2
was observed to decrease. When the relative IC50 of COX
inhibitors increased above 10, we observed a strong inhibition
on the production of PGI2, whereas the production of TXA2
was hardly affected. The value of PGI2/TXA2 became
signiﬁcantly smaller than that before the administration of
medicine. Cardiovascular side effects have been found in
selective COX-2 inhibitors (Rahman and Khan, 2004; Singh,
2004; Solomon et al, 2005), presumably due to the decrease in
PGI2/TXA2. Indeed, in our simulation, Vioxx was correctly
predicted to be a high cardiovascular risk. As COX inhibitors
failtocontrolinﬂammationsafely,licofelone,adualfunctional
inhibitor of COX-1/2 and 5-LOX, has been developed. This
compound was reported to be effective in inﬂammation
Table II Multi-target control solutions found by MTOI
No. PLA2 COX-2 PGES 5-LOX LTA4H COX-1 Frequency /SS
1 OO—— — O 1 0.0011
2 OOO——O 1 0.0011
3—OOO O O 5 0.002
4—OO— OO 5 0.0021
5——OO O — 2 0.0026
6 OOOO O O 5 0.0028
7—OOO— O 5 0.0033
8 OOO— OO 5 0.0034
9—O — OOO 5 0.0036
10 OO— OOO 5 0.0037
11 OOOO— O 5 0.0041
12 OO—— OO 5 0.0042
13 — O —— OO 5 0.0048
14 O — OO O — 1 0.0057
15 — — OO— — 2 0.0061
16 — — O — O — 3 0.0072
17 OO— O — O 5 0.0075
18 — O — O — O 5 0.01
19 O — O — O — 1 0.0123
20 O — OO— — 1 0.0241
21 O ——OO— 1 0.0431
22 O ——— O — 1 0.0569
23 O ——O — — 1 0.0624
The frequency of MTOI solutions appearing in ﬁve parameter sets was also
shown. The sensitivity /SS is averaged over the parameter sets in which the
solution appeared. ‘—’ denotes no regulation and ‘O‘ denotes that the
corresponding enzyme is inhibited.
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varo-Gracia, 2004; Bias et al, 2004; Rotondo et al, 2006). Our
simulation showed that licofelone can maintain the balance
between PGI2 and TXA2, and at the same time effectively
reduce PGE2 and LTB4 production.
Drug efﬁcacy prediction of MTOI solutions
Several promising MTOI solutions were selected for further
investigation. The ratio of PGI2/TXA2 was calculated as the
indicator for side effects. The relative [I]/Ki values of solutions
were taken from MTOI analysis. Simulation results are
summarized in Table IV. Unlike the currently used drugs that
inhibit only COX-1/2 (with the exception of licofelone, which
also inhibits 5-LOX), MTOI solutions achieved a balanced
control on the entire network. The ratio of PGI2/TXA2 was
almost unchanged after taking MTOI solutions, although the
production of LTB4 and PGE2 was inhibited effectively at the
same time. Recently, much attention has been drawn to the
two downstream drug targets: PGES and LTA4H, as their
inhibitors may produce fewer side effects when compared the
with upstream enzyme blockers (Fahmi, 2004; Haeggstrom,
2004). MTOI found that optimal therapeutic effects are
achieved only when the two targets or one of them in
combination with other targets are inhibited simultaneously;
for example, the combination of PGES and LTA4H and the
combination of COX-2/1 and LTA4H. Inhibiting more than one
drug target is important in anti-inﬂammatory treatment.
Figure 3 The distribution of [I]/Ki of MTOI solutions. (A) Inhibition against LTA4H, COX-1 and COX-2. (B) Inhibition against PLA2, LTA4H, COX-1 and COX-2.
Table III Efﬁcacy simulation of currently used medicines in AAnetwork
Inhibitor Relative IC50 Inhibition of PGE2 (%) Inhibition of LTB4 (%) [PGI2]/[TXA2]
Control — — — 0.6817
Aspirin IC50(COX-1:COX-2)¼0.01 90.0 — 5.1947
Ibuprofen IC50(COX-1:COX-2)¼0.5 90.0 — 3.5599
Naproxen IC50(COX-1:COX-2)¼0.7 90.0 — 2.2915
6-MNA IC50(COX-1:COX-2)¼1.5 90.0 — 2.2334
Acetaminophen IC50(COX-1:COX-2)¼1.6 90.0 — 2.1574
Indomethacin IC50(COX-1:COX-2)¼1.9 90.0 — 1.9613
Meloxicam IC50(COX-1:COX-2)¼18 90.0 — 0.5335
Nimesulide IC50(COX-1:COX-2)¼19 90.0 — 0.5207
Diclofenac IC50(COX-1:COX-2)¼29 90.0 — 0.4399
Celecoxib IC50(COX-1:COX-2)¼30 90.0 — 0.4347
Rofecoxib (VIOXX) IC50(COX-1:COX-2)¼267 90.0 — 0.2804
Licofelone IC50(5-LOX)¼0.18mM
IC50(COX-2)¼0.21mM
IC50(COX-1)¼1mM
96.5 90.0 0.6983
Thesame parameterset asin Table I andFigure3 wasusedhere.The ratioofPGI2/TXA2 thereﬂectspossible sideeffects of thedrug. After takingthemedicine,if PGI2/
TXA2 becomes much larger than the normal level, bleeding side effects may occur. If PGI2/TXA2 decreases signiﬁcantly, cardiovascular risks will be raised.
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targets are inhibited simultaneously, a mild inhibition of each
target is sufﬁcient to achieve effective control of LTB4 and
PGE2 production and there is a much larger therapeutic
window. For example, simultaneously inhibiting COX-2/1 and
LTA4H, the [I]/Ki of COX-2 should be 400 to achieve effective
treatment.InthecaseofsimultaneouslyinhibitingPLA2,COX-
2/1 and LTA4H, the value of [I]/Ki of COX-2 needed is reduced
to 80. This value is further reduced to 20 when all the six
targets are inhibited. The reduced inhibition intensity may
decrease the toxicity riskof the drugs.Furthermore, regulation
on multiple enzymes can maintain the PGI2/TXA2 ratio more
easily than single-target drugs. As discussed in the section of
‘MTOI solutions for the AAnetwork’, we found that the
intervention of more targets gave more robust solutions. This
may explain the possible beneﬁts of traditional Chinese
medicines (TCMs), in which mild control is directed to
multiple drug targets.
Discussion
We have developed a systematic method (MTOI) to search for
optimal interventions in a disease network. The basic concept
is simple: the goals are to identify effective points of
intervention and the optimal combinations of interventions
that restore the network to a normal state. Quantitatively,
optimization is carried out with an objective function that
speciﬁes the customer-deﬁned requirements of what the
normal state should be, including safety conditions. An MCSA
algorithm is employed here to optimize the network state with
perturbations on network components and/or interactions.
The end results include promising drug targets and optimal
solutions of their combinatorial intervention. We have applied
the method to a network responsible for inﬂammation—the
AAnetwork. We have demonstrated the utility and power of
the method with the robust identiﬁcation of the drug targets
and the multi-target intervention solutions that are both
effective and safe.
Discovering drug targets
MTOI systematically analyzes the conversion between the
diseaseand desired statesto identify potentialdrug targetsand
to ﬁnd multi-target intervention solutions with user-deﬁned
efﬁcacy and safety thresholds. Compared with the traditional
drug target search methods, such as parameter sensitivity
analysis (Palsson and Lee, 1993; Pant and Ghosh, 2005), MTOI
emphasizes the inﬂuence of the drug target candidate’s
activity on the entire network state. Thus, it can be regarded
as a network-state-based drug target sensitivity analysis
method. Instead of relying on individual parameters for target
identiﬁcation, MTOI dynamically perturbs and searches the
various combinations of the entire parameters of drug target
candidates to accurately and robustly identify the relationship
between target candidates and the network state. As a
comparison, we also performed single parameter sensitivity
analysis on the AAnetwork (Supplementary Table SV, see
details in Supplementary information). Although the top list
was consistent with the result of MTOI, the ways of invention
(upregulate or downregulate) cannot be predicted from the
analysis.
When applied to the AAnetwork, MTOI has succeeded in
identifying some well-known anti-inﬂammatory drug targets,
including PLA2, COX-2, 5-LOX, PGES and LTA4H. PLA2
regulates the metabolism of AA upstream in the network.
InhibitionofPLA2caneffectivelycontrolbothPGE2andLTB4,
but will also downregulate all the downstream AA metabolites
including vasoactive eicosanoids, which has important phy-
siological functions. COX-2 and 5-LOX have been studied
intensively and became regular anti-inﬂammatory drug
targets. Medicines against these two enzymes, respectively,
such as ibuprofen and zileuton, were developed for general
clinical treatment. PGES and LTA4H are recently discovered
downstream enzymes. Inhibitors against PGES or LTA4H
attracted much attention due to the anticipated reduction of
toxicity. MTOI has also identiﬁed several important enzymes,
for example, 15-LOX, CYP4F3, for which increased activity is
desired for anti-inﬂammatory treatment. Although it is
Table IV Efﬁcacy simulation of MTOI solutions in AAnetwork
[I]/Ki Inhibition of PGE2 (%) Inhibition of LTB4 (%) [PGI2]/[TXA2]
PLA2 COX-2 PGES 5-LOX LTA4H COX-1
Control 0 0 0 0 0 0 0 0 0.6817
1 0 400 0 0 100 56.5 97 97 0.6843
2 14 80 0 0 50 35 97 97 0.6857
3 12 60 0 60 40 13 97 97 0.6855
4 9 20 10 50 30 26 97 97 0.6823
5 0 0 20000 0 45 0 97 95 0.5405
6 0 200 50 0 45 26.5 97 95 0.6853
7 0 200 50 60 30 32.5 97 95 0.6833
8 0 450 0 1200 0 95 97 97 0.6819
9 0 450 0 80 50 79 97 97 0.6817
10 0 200 50 1200 0 40.5 97 97 0.6824
11 250 5000 0 0 0 5000 98 95 0.6255
12 250 5000 5000 0 0 5000 98 95 0.625
13 15 190 0 90 0 190 98 95 0.6837
14 15 190 190 90 0 190 98 95 0.6832
15 15 105 105 0 25 105 98 95 0.6835
The same parameter set used is the same as in Figure 3. In the same way, the ratio of PGI2/TXA2 reﬂects possible side effects of the drug. After taking the medicine, if
PGI2/TXA2 becomes much greater than the normal level, bleeding side effects may occur. If PGI2/TXA2 decreases signiﬁcantly, cardiovascular risks will be raised.
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result may be useful to understand elevated disease suscept-
ibilities or variations in drug response among individuals due
to single nucleotide polymorphism (Shastry, 2005).
Finding multiple target intervention solutions
Identiﬁcation of optimal multi-target intervention solutions is
thecorefunctionofMTOI.Thecomplexityofanetwork,dueto
connectedness, feedback, cross talk and so on, is exploited
here to provide the researchers multiple choices for interven-
tion solutions. Moreover, the desired network state is
customer-designed by the user. This allows MTOI to be
applicable in the regulation and intervention of other kinds
of networks, for example, in studies of pesticides.
The efﬁcacy of currently used NSAIDs has been correctly
predicted by the AAnetwork model. Except for licofelone,
these compounds were found to have side effects both
clinically and in our simulation. As MTOI can correctly
reproduce the known side effects of NSAIDs, one may apply
it in predicting the possible side effects for new anti-
inﬂammation drugs targeting the AAnetwork. Furthermore,
MTOI study also gave several novel multi-target intervention
solutionsfortheAAnetworkcontrolwithhighefﬁcacyandlow
toxicity. Although, theoretically it is better to inhibit all the six
enzymes at the same time, practically, it might be difﬁcult to
design one medicine that can inhibit all the six enzymes
simultaneously or to use a cocktail containing six different
inhibitors.To simplify the case, we can start from the solutions
with fewer enzymes. For example, we believe that there are
severalsuch solutions that are ratherpromisingfordeveloping
anti-inﬂammation drugs: (1) the combination of PGES and
LTA4HandthecombinationofCOX-2/1andLTA4H.Thesetwo
solutions basically involve only two targets and should be
relatively straightforward to achieve. However, care should be
taken to make sure that the inhibitors should be used only in
the proper dosing range. The valid [I]/Ki range is quite narrow
for LTA4H in the PGES and LTA4H solution, and the ratio of
inhibition for COX-1/COX-2 should be maintained in a
narrow range for the COX-2/1 and LTA4H solution. (2) The
combination of PLA2, 5-LOX and COX-2/1 or the combination
of PLA2, COX-2/1 and LTA4H. With more targets that are
inhibited, the dosing ranges for these two solutions are much
larger, making them very attractive candidates for multi-target
drug design.
Our MTOI study suggested that optimal solutions often
involve mild but simultaneous interventions of multiple
targets. This is reminiscent of TCM in which multiple targets
are intervened with mild or low intensity. It would be
interesting to explore the molecular mechanisms of TCM
along this line. Of course, the targets of the most TCM are
unknown, which presents a signiﬁcant challenge.
Multi-target drug design at systems level
Givensufﬁcient knowledge about the disease-related network,
our results suggest that computational methods can play an
important and unique role in the new era of network-based
drug design. Construction of a network that is reasonably
complete is the ﬁrst key step. However, as almost surely the
network is incomplete and with many parameters being
unknown, a major challenge is to devise a robust computa-
tional algorithm that is able to extract desirable information
based more on the overall structure of the network than on
individual parameters.In principle,it isdifﬁcultto knowwhen
the knowledge about a network is sufﬁcient to apply a
network-based drug discovery method. One way to test this
istoperturbthenetworkandseehowthesolutionschange.We
have constructed a simpliﬁed AAnetwork model (Figure 4,
parameters are summarized in Supplementary Table SIII)
using partial information of the network and applied MTOI to
this model. In the simpliﬁed model, only the disease-related
metabolites and enzymes were included and unknown
parameters were evaluated by parameter ﬁtting (see details
in Supplementary information). MTOI has identiﬁed 14 multi-
target solutions in the simpliﬁed AAnetwork model (Supple-
Figure 4 The simpliﬁed network of arachidonic acid metabolism in human PMN, EC and PLT. The separate AAnetworks in PMN, EC and PLT can be found in
Supplementary Figure S2.
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of the full model (Table II). With the fast accumulation of
experimental data and more disease networks revealed, we
expect an increasingly critical role for computational ap-
proaches in systems drug design.
Materials and methods
Finding multi-target intervention solutions
in disease network
MTOI contains two stages. MCSA is employed as the main optimiza-
tiontoolinbothstages.Theprocedureofstage1includesthefollowing
steps:
Step 1. Deﬁne the disease and desired states. A state in the MTOI
program is deﬁned as a steady or temporal state of the network, which
can be a collection of concentrations of proteins and/or metabolites,
metabolic ﬂuxes or any other relevant information, for example, the
temporal behavior of the network within some time window.
Generally, the disease state can be obtained by experimental data
from patients or cells in abnormal conditions. The desired state is
speciﬁed by researchers, which can be the normal physiological state
of the network.
Step 2. Select reactions that can be controlled by drugs. Deﬁne a
quantity that controls the corresponding reaction rate as the activity of
the drug target candidate. For example, if the target is an enzyme, the
activity is deﬁned as Kcat [E]/Km.
Step 3. Starting froma randomlyselected set of the activities of drug
target candidates, perform MCSA to drive the system toward the
desired state. The activities of drug target candidates are perturbed in
MCSA, whereas the other parameters are maintained at the same
valuesofthediseasestate.Thedifferencebetweenthepresentnetwork
and desired states is used as the objective function.
Step 4. Record as ‘acceptable’ the set of the drug target candidates’
activities, when the desired state is reached by MCSA. Calculate the
standard deviation of the activities of each drug target candidate over
all acceptable sets:
s:d:i ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
P n
j¼1
ðAi;j    AiÞ
2
n   1
v u u u t
ð1Þ
where Ai,j is the activity of the ith drug target candidate in the jth set
and  Ai ¼ 1
n
Pn
j¼1 Ai;j is the average activity of the candidate over all
‘acceptable’ sets.
Step 5. Calculate the m.d. of the activity of drug target candidates
between the desired and disease states:
m:d:i ¼ medfDAi;1;    DAi;j;    DAi;ngð 2aÞ
DAi;j ¼ Ai;j   Adisease;i ð2bÞ
where Adisease,i is the activity of the ith candidate in the disease state.
Use |m.d.i/s.d.i| to determine the importance of the drug target
candidate and the sign of m.d.i to decide whether inhibition or
activation should be performed in the treatment.
Step6.Repeatsteps3–5untils.d.andm.d.convergetostablevalues
for all drug candidates (see details in Supplementary information).
Stage 1 can be skipped if the drug targets have been identiﬁed by
experiments or other methods. After identifying drug targets in the
network, one starts stage 2, which includes the following steps:
Step1.Addreactantsofdrugsagainsttheselecteddrugtargetsinthe
network. The reactants inﬂuence the ﬂuxes and rates of the target
reactions in different ways depending on speciﬁc reaction kinetics. For
example, if the target is an enzyme and the reaction has the Michaelis–
Menten kinetics:
d½S 
dt
¼
Kcat½Et ½S 
Km þ½ S 
ð3Þ
where [S] is the concentration of the substrate, [Et] the total
concentration of the enzyme, Kcat turnover number, Km Michaelis–
Mentenconstant,acompetitivereversibleinhibitorIwouldchangethe
equation (3) into
d½S 
dt
¼
Kcat½Et ½S 
Kmð1 þ½ I =KiÞþ½ S 
ð4Þ
where [I] is the concentration of the inhibitor and Ki the inhibition
constant: Ki ¼½ E ½I =½EI . [I]/Ki is deﬁned as the intensity of the drug
inﬂuence against the drug target.
Step 2. Starting from the disease state and selecting a random set of
intensities of drug inﬂuence against all drug targets, perform MCSA to
drive the system toward the desired state. Only the intensities of drug
inﬂuence are perturbed, whereas other parameters in the network are
maintained at the values of the disease state. The difference between
the present network and desired states is used as the objective
function.
Step 3. Record as ‘acceptable’ the set of the intensities of the drugs
against all targets, when the desired state is reached by MCSA. This
‘acceptable’setisonemulti-targetinterventionsolutionforthedisease
network.
Step 4. Repeat steps 2 and 3 until many solutions are found and the
resultsareclusteredinthespaceofintensitiestoﬁnddistinctsolutions.
Construction of the AAnetwork model in human
PMN, EC and PLT cells
The AAnetwork in human PMN, EC and PLT cells was set up based
on our previous study and experimental data was published (see
details in Supplementary information). As the ratio of PMN, EC and
PLT depends on the size of the blood vessel, we simulated the
metabolism of AA in a 1-cm long and 50-mm diameter vessel. The
concentration of PMN and PLT in the model is set to the same value as
in human blood, that is, 4500 and 2.5 10
5 cells/ml, respectively, so
that the number of PMN and PLT in the considered region was 88 and
4908, respectively. The diameter of PMN and PLT was set to 10 and
2mm,respectively.ThenumberofECdependsonthesizeofthevessel.
Only the inner layer of EC was considered and the diameter of EC was
set to 50mm, thus in the considered region the number of EC in the
model was 628.
On the basis of the AAnetwork of Figure 2, a set of ODEs
were constructed to describe cell behavior in inﬂammation. The
ode15s routine of Matlab 6.5 (The Mathworks Inc., http://
www.mathworks.com) was used to integrate the ODEs. Michaelis–
Menten equations (equation (3)) were used to describe enzyme
catalytic reactions in the network. Equation (4) was employed if
competitive reversible inhibitors were involved in the catalysis. If the
inhibition is irreversible, we assumed that the enzyme would decay
according to
d½E 
dt
¼  K½E ½I ð 5Þ
When activators were involved in the catalysis, we used:
d½S 
dt
¼
Kcatð1 þð ½ U =KIÞþð ½ U0 =KI0ÞÞ½Et ½S 
Km þ½ S 
ð6Þ
To describe the reaction kinetics, where [U] is the concentration of the
activator and KI is a constant.
Whenupregulationoccurredthroughtranscription,wedescribedits
effect with the following equation:
d½E 
dt
¼
k½g 
2
½g 
2 þ K2 ð7Þ
where [g] is the concentration of the metabolite upregulating the
transcription of the enzyme, K and k are constants.
MTOI application in the AAnetwork model
The MTOI procedure described earlier was applied in the AAnetwork
model to ﬁnd multi-target anti-inﬂammatorycontrolsolutions. Stage 1
of the procedure includes:
Step 1. Deﬁne the disease and desired states. The disease state in
AAnetwork was described by parameter sets derived from parameter
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PMN, EC and PLT cells’). The desired state was a state where
the 1h cumulative production of LTB4 and PGE2 is less than 10% of
that in the disease state. The ﬂuxes of other metabolites are
not monitored.
Step2. All the enzymesin the AAnetwork were selectedas potential
drug target candidates. The activity of an enzyme was deﬁned as
A ¼
Kcat½E 
Km
ð8Þ
Step 3. Perform MCSA as described earlier to ﬁnd the desired state.
In the process, the initial temperature was set to be 501C, the
maximum number of Monte Carlo attempts under the same
temperature was 500, the constant in the exponential cooling scheme
was 0.7, and the ﬁnal temperature in MCSA was 5 10
 6.
The perturbed range of enzyme activity was [0.01Adisease,1 0 0 Adisease].
The objective function was
Fobj ¼
CT;net
CT;disease
  
LTB4
þ
CT;net
CT;disease
  
PGE2
ð9Þ
where CT,net and CT,disease were the 1h cumulative production
of the metabolite in the present network and disease states,
respectively. Equation (9) optimized the production of LTB4 and
PGE2towardzero.Inthecalculation,whentheproductionofLTB4and
PGE2 was below 10% of that in the disease state, respectively,
the corresponding set of enzyme activities was accepted as the
desired state.
Step 4. Record as ‘acceptable’ the set of activities of the drug target
candidates, when the desired state is reached by MCSA. Standard
deviation of enzyme activity over all accepted sets was calculated as
s:d:i ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
X n
j¼1
log10
Adesired;i;j
Adisease;i
  log10
Adesired;i
Adisease;i
   2
=n   1
v u u t ð10Þ
where Adesired,i,j is the activity of the ith drug target candidate in the jth
desiredset.Becauseoftherequirementofnormalization,hereweused
log10 ðAdesired;i;j=Adisease;iÞ for s.d. calculation instead of Ai,j as in
equation (1). This change does not inﬂuence the result on drug targets
selection.
Step 5. Mead deviation of enzyme activity between the desired and
disease states was calculated as
m:d:i ¼ medfDAi;1;    DAi;j;    DAi;ngð 11aÞ
DAi;j ¼ log10 Adesired;i;j   log10 Adisease;i ð11bÞ
Again, we used equation (11) instead of (2) due to normalization.
Step 6. Repeat steps 3–5 until s.d. and m.d. converge.
The procedure of stage 2 was:
Step 1. Add reactants of drugs against the selected drug targets
in the network. Drugs in AAnetwork were assumed to be
competitive reversible inhibitors, thus [I]/Ki was deﬁned as inhibition
intensity.
Step 2. Perform MCSA to ﬁnd the desired state. The high
temperature, the maximum number of Monte Carlo attempts under
the same temperature, the constant in the exponential cooling scheme
and the ﬁnal temperature in MCSA adopted the same value as those in
stage 1. [I]/Ki was perturbed in a range of [0 100000]. The objective
function was
F0
obj ¼
CT;net
CT;disease
  
LTB4
 0:1
       
        þ
CT;net
CT;disease
  
PGE2
 0:1
       
       
þ
CT;PGI2
CT;TXA2
  
net
 
CT;PGI2
CT;TXA2
  
disease
 1
       
       
ð12Þ
This objective function was set according to the following considera-
tions: in the desired state, the production of LTB4 and PGE2 was below
10% of that of the disease state and the change of PGI2/TXA2 was less
than 20%.
Step 3. Record as ‘acceptable’ the set of the intensities of drug
inﬂuence, when the desired state is reached by MCSA.
Step 4. Repeat the above steps until no more new solutions are
found.
In the end, we also calculated the sensitivity of drugs’ safety and
effectiveness to [I]/Ki as
S ¼
DF
0
obj=F
0
obj
P 5
j¼1
Dð½I =KiÞj=ð½I =KiÞ
ð13Þ
where Fobj was calculated with equation (12). S measures how
sensitive the drug effects are to small changes in the inhibition
intensities.
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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